GSK submits landmark IMPACT data to US regulatory authority to support expanded label for Trelegy Ellipta
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the filing of a supplemental New Drug Application (sNDA) with the US Food and Drug Administration (FDA) for the use of Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol, 'FF/UMEC/VI') for an expanded indication for the maintenance treatment of airflow obstruction and reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD).
Boehringer Ingelheim makes many of its best molecules openly available to the scientific community via opnMe.com to unlock their full potential
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim has announced the launch of opnME.com, a new platform offering free and open access to selected pre-clinical molecules for non-clinical investigation to scientists worldwide. Through opnME.com, molecules for some of the most relevant targets in biomedical research are shared, thereby creating possibilities for further independent and collaborative discovery as well as the identification of novel treatment approaches for patients.
Roche to acquire Viewics, Inc. to provide data-driven lab business analytics and add further digital capabilities along the laboratory value chain
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced an agreement with Viewics, Inc., a privately held software company focused on laboratory business analytics. Under the agreement, Roche is acquiring all shares of the company. The acquisition, which is subject to customary closing conditions, is expected to close on November 21, 2017.
Novartis, ASCP and ACS join forces to fight cancer in Ethiopia, Uganda and Tanzania
- Details
- Category: Novartis
Novartis, the American Society for Clinical Pathology (ASCP) and the American Cancer Society (ACS) will work together to devise a common approach to improve access to cancer treatment in Sub-Saharan Africa. Each partner brings unique expertise in cancer diagnosis and treatment. This complements the work the Clinton Health Access Initiative (CHAI) is doing to improve access to affordable, quality-approved oncology medicines in the region.
Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer
- Details
- Category: Bayer
Bayer has entered into an exclusive global collaboration with Loxo Oncology, Inc., a biopharmaceutical company based in Stamford, Connecticut, US, (NASDAQ: LOXO) for the development and commercialization of larotrectinib (LOXO-101) and LOXO-195. Both compounds are being investigated in global studies for the treatment of patients with cancers harboring tropomyosin receptor kinase (TRK) gene fusions,
Pfizer receives FDA approval for SUTENT® (sunitinib malate) as first and only adjuvant treatment for adult patients at high risk of recurrent renal cell carcinoma
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include the adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma (RCC) following nephrectomy (surgical removal of the cancerous kidney).
Fasenra (benralizumab) receives US FDA approval for severe eosinophilic asthma
- Details
- Category: AstraZeneca
AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab) for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.
More Pharma News ...
- New Novartis Entresto® real world evidence data shows beneficial impact on quality of life in people living with heart failure
- BMS-Pfizer Alliance to unveil real-world data analyses - cost, safety and comparative effectiveness findings associated with oral anticoagulants in non-valvular atrial fibrillation
- Boehringer Ingelheim and MiNA Therapeutics to develop novel treatment approaches for fibrotic liver diseases
- Sanofi, Principia agree to develop multiple sclerosis drug candidate
- Spark Therapeutics and Pfizer amend license agreement for investigational SPK-9001 in hemophilia B
- Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®
- Amgen and Novartis announce expanded collaboration with Banner Alzheimer's Institute in pioneering prevention program